High use of short-acting β
Journal
ERJ open research
ISSN: 2312-0541
Titre abrégé: ERJ Open Res
Pays: England
ID NLM: 101671641
Informations de publication
Date de publication:
May 2023
May 2023
Historique:
received:
20
12
2022
accepted:
23
04
2023
medline:
21
6
2023
pubmed:
21
6
2023
entrez:
21
6
2023
Statut:
epublish
Résumé
Short-acting β This observational study identified COPD patients in primary care medical records in Sweden. Data were linked to the National Patient Registry, the Prescribed Drug Registry and the Cause of Death Registry. The index date was 12 months after the date of COPD diagnosis. During a 12-month prior to index baseline period, information on SABA use was collected. Patients were followed with respect to exacerbations and mortality for 12 months post index. Of the 19 794 COPD patients included (mean age 69.1 years, 53.3% females), 15.5% and 7.0% had collected ≥3 or ≥6 SABA canisters during the baseline period, respectively. A higher level of SABA use (≥6 canisters) was independently associated with a higher risk of both moderate and severe exacerbations (hazard ratio (HR) 1.28 (95% CI 1.17‒1.40) and 1.76 (95% CI 1.50‒2.06), respectively) during follow-up. In total, 673 (3.4%) patients died during the 12-month follow-up period. An independent association was found between high SABA use and overall mortality (HR 1.60, 95% CI 1.07‒2.39). This association, however, was not found in patients using inhaled corticosteroids as maintenance treatment. In COPD patients in Sweden, high SABA use is relatively common and associated with a higher risk of exacerbations and all-cause mortality.
Sections du résumé
Background
UNASSIGNED
Short-acting β
Methods
UNASSIGNED
This observational study identified COPD patients in primary care medical records in Sweden. Data were linked to the National Patient Registry, the Prescribed Drug Registry and the Cause of Death Registry. The index date was 12 months after the date of COPD diagnosis. During a 12-month prior to index baseline period, information on SABA use was collected. Patients were followed with respect to exacerbations and mortality for 12 months post index.
Results
UNASSIGNED
Of the 19 794 COPD patients included (mean age 69.1 years, 53.3% females), 15.5% and 7.0% had collected ≥3 or ≥6 SABA canisters during the baseline period, respectively. A higher level of SABA use (≥6 canisters) was independently associated with a higher risk of both moderate and severe exacerbations (hazard ratio (HR) 1.28 (95% CI 1.17‒1.40) and 1.76 (95% CI 1.50‒2.06), respectively) during follow-up. In total, 673 (3.4%) patients died during the 12-month follow-up period. An independent association was found between high SABA use and overall mortality (HR 1.60, 95% CI 1.07‒2.39). This association, however, was not found in patients using inhaled corticosteroids as maintenance treatment.
Conclusion
UNASSIGNED
In COPD patients in Sweden, high SABA use is relatively common and associated with a higher risk of exacerbations and all-cause mortality.
Identifiants
pubmed: 37342089
doi: 10.1183/23120541.00722-2022
pii: 00722-2022
pmc: PMC10277875
pii:
doi:
Types de publication
Journal Article
Langues
eng
Informations de copyright
Copyright ©The authors 2023.
Déclaration de conflit d'intérêts
Conflict of interest: C. Janson has received payments for educational activities from AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Novartis, and Teva, and has served on advisory boards arranged by AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Novartis, and Teva. F. Wiklund is employed at Statisticon of which AstraZeneca is a client. Conflict of interest: G. Telg and G. Stratelis are employed by AstraZeneca. H. Sandelowsky has received honoraria for educational activities from Boehringer Ingelheim, Novartis, AstraZeneca, Chiesi, and TEVA, an unrestricted research grant from AstraZeneca, and has served on advisory boards arranged by AstraZeneca, Novartis, Chiesi, and GlaxoSmithKline.
Références
Eur Respir J. 2022 May 5;59(5):
pubmed: 34561293
BMC Pulm Med. 2015 Aug 21;15:97
pubmed: 26293575
Respir Med. 2019 Oct - Nov;158:110-113
pubmed: 31655317
Am J Epidemiol. 2011 Mar 15;173(6):676-82
pubmed: 21330339
Eur Respir J. 2013 Dec;42(6):1472-83
pubmed: 23722617
Eur Respir J. 2010 May;35(5):1022-30
pubmed: 19897555
Med Care. 2005 Nov;43(11):1130-9
pubmed: 16224307
Int J Chron Obstruct Pulmon Dis. 2020 Oct 28;15:2673-2682
pubmed: 33149565
Int J Chron Obstruct Pulmon Dis. 2020 Nov 27;15:3123-3134
pubmed: 33273814
Respir Res. 2020 Oct 22;21(1):280
pubmed: 33092591
Eur Respir J. 2020 Apr 16;55(4):
pubmed: 31949111
Int J Chron Obstruct Pulmon Dis. 2022 May 20;17:1205-1217
pubmed: 35645559
Int J Chron Obstruct Pulmon Dis. 2022 Aug 09;17:1769-1780
pubmed: 35971390
Respir Med. 2016 Jul;116:100-6
pubmed: 27296828
Respir Med. 2014 Sep;108(9):1345-54
pubmed: 25002194
Eur Respir J. 2022 Aug 10;60(2):
pubmed: 35777767
Eur Respir J. 2005 Sep;26(3):406-13
pubmed: 16135720
Lancet. 2012 Dec 15;380(9859):2095-128
pubmed: 23245604
Proc Am Thorac Soc. 2004;1(3):200-6
pubmed: 16113435
Lancet Respir Med. 2022 May;10(5):447-458
pubmed: 35279265
J Allergy Clin Immunol. 1999 Aug;104(2 Pt 2):S18-30
pubmed: 10452785
Int J Chron Obstruct Pulmon Dis. 2019 Sep 03;14:2003-2013
pubmed: 31564848
Adv Ther. 2020 Mar;37(3):1124-1135
pubmed: 31981105
Int J Chron Obstruct Pulmon Dis. 2018 Jan 11;13:275-285
pubmed: 29391785
N Engl J Med. 2020 Jul 2;383(1):35-48
pubmed: 32579807
Am J Respir Crit Care Med. 2000 May;161(5):1608-13
pubmed: 10806163
Am J Respir Crit Care Med. 2003 Apr 15;167(8):1090-5
pubmed: 12684248
J Allergy Clin Immunol Pract. 2022 Sep;10(9):2297-2309.e10
pubmed: 35364341
Respir Res. 2018 Dec 13;19(1):251
pubmed: 30545350
Am J Respir Crit Care Med. 2008 Feb 15;177(4):396-401
pubmed: 18048806
Respir Res. 2017 May 8;18(1):86
pubmed: 28482883